References
- Yagoda A. Chemotherapy of urothelial tract tumors. Cancer 1987; 60: 574–585
- Sternberg CN, Yagoda A, Scher HI. MVAC for advanced transitional cell carcinoma of the urothelium: Efficacy and pattern of response and relapse. Cancer 1989; 64: 2448–2458
- Boutan-Laroze A., Mahjoubi M, Droz JP. M-VAC (methotrexate, vinblastine, doxorubicine and cisplatine) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience. Eur J Cancer 1991; 27: 1690–1694
- Mahjoubi M, Kattan J, Droz JP. Feasibility trial of a combination of vinorelbine, ifosfamide, fluoro-uracil and folinic acid (VIF regimen) in advanced urothelial cancer. Eur J Cancer 1993; 29A: 285–286
- Duchek M, Edsmyr F Naslund. 1: 5-fluoro-uracil the treatment of recurrent cancer of the urinary bladder. Bladder Tumors and Other Topics in Urologic Oncology, M. Pavone-Macawso, P. Smith, F. Edsmyr. Plenum Press, New York 1980; 381–385; 381–385
- Fossa SD, Gudmundsun TE. Single drug chemotherapy with 5-FU and adriamycin in metastatic bladder carcinoma. Br J Urol 1981; 53: 320–323
- Knight EW, Pagand M, Hahn RG. Comparison of 5-FU and doxorubicin in the treatment of carcinoma of the bladder. Cancer Treat Rep 1983; 67: 514–515
- Nazli G, Khaled H, Abdelwareth A. Epirubicin, ifosfamide combination chemotherapy in invasive bladder cancer. Proc Am Soc Clin Oncol 1990; 9: 137
- World Health Organization. WHO Handbook of Reporting the Results of Cancer Treatment. WHO offset publication, Geneva 1979; 48
- Logothetis C, Hossan E, Sella A. Fluorouracil and recom-binant human interferon alpha-2A in the treatment of metastatic chemotherapy-refractory urothelial tumors. J Natl Cancer lnst 1991; 83: 285–288
- Witte R, Loehrer P., Dreicer R. Ifosfamide in advanced urothelial carcinoma: An ECOG trial. Proc Am Soc Clin Oncol 1993; 12: 230
- Becher R, Hofeler H, Kloke O. Ifosfamide. methotrexate and 5-fluoro-uracil in advanced pretreated breast cancer. Semin Oncol 1989; 16: 56–59, (suppl 3)
- Logothetis C, Dexeus F, Sella A. Escalated MVAC (MTX 30 mg/m2, adriamycin 60 mg/m2. vinblastine 4 mg/m2, cisplatin 100 mg/m2) with recombinant human granulocyte macrophage stimulating factor for patients with advanced and chemotherapy refractory urothelium tumors. A phase I study. J Clin Oncol 1990; 8: 1050–1055
- Kattan J, Culine S, Theodore C, Droz JP. Second-line MVAC therapy in patients previously treated with the M-VAC regimen for metastatic urothelial cancer. Ann Oncol 1993; 4: 793–794
- Seidman AD, Scher HI, Heinemann MH. Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 1991; 68: 2561–2565